PGI28 Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstan

Bektur, C; Nurgozhin, T; Abdukhakimova, D; C, Bektur

PGI28 Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstan

Date

2015-11-01

Authors

Bektur, C

C, Bektur

Nurgozhin, T

Abdukhakimova, D

Publisher

Value in Health

Abstract

Hepatitis C Virus(HCV) is a growing health problem in the world. The aim of this study is to estimate a cost-effectiveness of a triple therapy(TT) with simeprevir compared to a TT with telaprevir for the previously treated with double therapy HCV patients in Kazakhstan.

Citation

C Bektur, T Nurgozhin, D Abdukhakimova, PGI28 - Cost-Effectiveness of Simeprevir Vs. Telaprevir for The Triple Therapy of Hepatitis C In Kazakhstan, In Value in Health, Volume 18, Issue 7, 2015, Page A627